Japanese Catheter Ablation Registry (J-AB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03729232|
Recruitment Status : Recruiting
First Posted : November 2, 2018
Last Update Posted : January 1, 2019
|Condition or disease|
|Catheter Ablation Cardiac Arrhythmias|
Japanese Cather Ablation (J-AB) Registry is a nationwide, multicenter, observational registry, performed by Japanese Heart Rhythm Society, collaborated with National Cerebral and Cardiovascular Center.
This study is a voluntary nationwide registry and data are collected prospectively using a Research Electronic Data Capture (REDCap) system. Detailed data collection including antiarrhythmic medication is also performed at every September. The acute success rate at discharge and the complications associated with ablation procedure will be collected in all cases. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria. Based on the provided information, the annual incidence and predictive factors for outcome will be investigated by the event assessment committee.
|Study Type :||Observational|
|Estimated Enrollment :||400000 participants|
|Official Title:||Japanese Catheter Ablation Registry|
|Actual Study Start Date :||July 1, 2017|
|Estimated Primary Completion Date :||March 31, 2030|
|Estimated Study Completion Date :||March 31, 2030|
- Number of patients with recurrence of targeted arrhythmia [ Time Frame: Through discharge from hospital, approximately up to 1 weeks ]
- Number of deaths [ Time Frame: Through discharge from hospital, approximately up to 1 weeks ]All-cause death, cardiovascular death, and procedure-related death
- Number of patients with treatment-related complications [ Time Frame: 3 months ]Bleeding events, embolic events, other all complications. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03729232
|Contact: Kengo Kusano, MD, PhDemail@example.com|
|National Cerebral and Cardiovascular Center||Recruiting|
|Suita, Osaka, Japan, 565-8565|
|Contact: Kengo Kusano, MD, PhD +81-6-6833-5012 firstname.lastname@example.org|
|Principal Investigator:||Teiichi Yamane, MD, PhD||The Jikei University School of Medicine|
|Principal Investigator:||Kengo Kusano, MD, PhD||National Cerebral and Cardiovascular Center|